Nasdaq Axes 126 Companies from Biotech Index; Cut Includes Genomics Cos. | GenomeWeb

NEW YORK, Jan 22 – The Nasdaq said Monday it had slashed the number of companies it would include in its biotechnology index from 202 to 76, including a number of genomics companies that recently raised tens of millions of dollars last year but have since seen their share prices fall.

The change in the index will be effective Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.